Our use of cookies

We use necessary cookies to make our site work.

For more detailed information about the cookies we use, see our Cookie Policy.


Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Therapy Areas in Europe

Good health and wellbeing is a universal aspiration, and we continue to seek ways to help patients in achieving better health and a better quality of life. In Europe our pharmaceutical business employs around 500 people, all of whom channel their energy into exploring solutions that we hope will make a difference to patients’ lives. We aim to help people with diseases that range from those affecting millions to those that affect relatively few. The health and wellbeing of patients is our primary focus, and we put the needs and views of patients, carers and healthcare professionals at the heart of the work we do. We aim to help patients in the following therapy areas:

Neuroscience

For over 30 years, we have worked in the area of mental health, focusing on treatments for schizophrenia and bipolar disorder.

Haemato-oncology

We are currently focusing on haematological malignancies, such as acute myeloid leukaemia.

 

Nephrology and Immunology

We endeavour to develop treatments in areas of high unmet medical need, such as autosomal dominant polycystic kidney disease (ADPKD), lupus nephritis and hereditary angioedema. 

 

Date of preparation: July 2024 | Reference NOR-NPR-2400008

This website is for all those with an interest in Otsuka Pharmaceutical in the Nordics and BeNeLux.